Monday, 13 April 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 13 April 2026
News

8 deaths overseas but no TGA alert

Posted 13 April 2026 AM

The FDA has issued a warning of fatalities associated with a rare disease drug which is also listed on the PBS, but the TGA is withholding similar action as no such adverse events have occurred in Australia.

"FDA is alerting patients and health care professionals about serious postmarketing cases, including fatal cases, of drug-induced liver injury (DILI) associated with Tavneos," the FDA said at the end of March. "Some cases involved vanishing bile duct syndrome (VBDS), which is characterised by progressive destruction and disappearance of the bile ducts in the liver."

To see the whole article, please login

Popular

Who's joined the TGA's review list?
$210K tit-for-tat Aussie Code fines
Meet industry's $50M-a-year Boss
New Medical Affairs leader named
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home